163 related articles for article (PubMed ID: 9018915)
21. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.
Acquaviva G; Visani M; Repaci A; Rhoden KJ; de Biase D; Pession A; Giovanni T
Histopathology; 2018 Jan; 72(1):6-31. PubMed ID: 29239040
[TBL] [Abstract][Full Text] [Related]
22. Differentiated thyroid cancer--papillary and follicular carcinomas.
Goepfert H; Callender DL
Am J Otolaryngol; 1994; 15(3):167-79. PubMed ID: 8024104
[No Abstract] [Full Text] [Related]
23. Thyroid carcinoma: diagnostic and therapeutic approach; genetic background (review).
Lewinski A; Ferenc T; Sporny S; Jarzab B
Endocr Regul; 2000 Jun; 34(2):99-113. PubMed ID: 10991553
[No Abstract] [Full Text] [Related]
24. Prognostic Classifier Based on Genome-Wide DNA Methylation Profiling in Well-Differentiated Thyroid Tumors.
Bisarro Dos Reis M; Barros-Filho MC; Marchi FA; Beltrami CM; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
J Clin Endocrinol Metab; 2017 Nov; 102(11):4089-4099. PubMed ID: 28938489
[TBL] [Abstract][Full Text] [Related]
25. [Correlations between cytology and histology in thyroid pathology. Case 2. Possible malignant lesion (insular carcinoma/poorly differentiated follicular carcinoma)].
Cochand-Priollet B
Ann Pathol; 2009 Apr; 29(2):91-4. PubMed ID: 19364580
[No Abstract] [Full Text] [Related]
26. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
[TBL] [Abstract][Full Text] [Related]
27. [Pathologic features of recently identified renal cell carcinoma].
Fan X; Rao Q; Zhang LH
Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):569-73. PubMed ID: 24246930
[No Abstract] [Full Text] [Related]
28. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
29. [Papillary and vesicular carcinoma of the thyroid: diagnostic problems and new data].
Belleannee G; Trouette H; De Mascarel A
Ann Pathol; 2000; 20 Suppl():S37-9. PubMed ID: 11261295
[No Abstract] [Full Text] [Related]
30. Typical thyroid-type carcinoma arising in struma ovarii: a report of 4 cases and review of the literature.
Roth LM; Miller AW; Talerman A
Int J Gynecol Pathol; 2008 Oct; 27(4):496-506. PubMed ID: 18753973
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in thyroid carcinomas.
Fonseca E; Soares P; Rossi S; Sobrinho-Simões M
Verh Dtsch Ges Pathol; 1997; 81():82-96. PubMed ID: 9474858
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.
Paulson VA; Shivdasani P; Angell TE; Cibas ES; Krane JF; Lindeman NI; Alexander EK; Barletta JA
Thyroid; 2017 Apr; 27(4):506-511. PubMed ID: 28114855
[TBL] [Abstract][Full Text] [Related]
33. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
36. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
37. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
38. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
39. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
40. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in thyroid tumor classification.
Kakudo K; El-Naggar AK; Hodak SP; Khanafshar E; Nikiforov YE; Nosé V; Thompson LDR
Pathol Int; 2018 Jun; 68(6):327-333. PubMed ID: 29675873
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
